Geert D’Haens

This session presents the best submitted clinical abstracts as determined by their specific council sections…

The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…

The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…

BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…

BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…

Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…

BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…

BACKGROUND: The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease…

Management strategies and clinical outcomes vary substantially in patients newly-diagnosed with Crohn’s disease…

BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…